Why does lung cancer recur? It’s all in the genes, finds new study
Lung cancer is the leading cause of cancer deaths worldwide, mainly because it gets detected late. The discovery by the ...
A post-treatment blood test could inform future cancer therapy decisions
In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that ...
pharmaphorum4d
Kelun-Biotech first to bag TROP2 approval in lung cancer
Sichuan Kelun-Biotech Biopharma has become the first drugmaker to usher a TROP2-targeted antibody-drug conjugate to ...
Mirage News18h
Blood Test Post-Treatment May Guide Cancer Therapy
In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that measures the presence of ...
Targeted Oncology6d
Exploring Targeted Treatments and Their AEs in EGFR-Mutated NSCLC
During a live event, Alexander I. Spira, MD, PhD, and participants discuss efficacy, adverse events, and sequencing of EGFR-mutated NSCLC treatments.
Pharmabiz5d
China NMPA approves Kelun-Biotech’s TROP2 antibody drug conjugate sac-TMT for marketing in second indication
Biotech’s TROP2 antibody drug conjugate sac-TMT for marketing in second indication: Chengdu, China Wednesday, March 12, 2025, 11:00 Hrs [IST] Sichuan K ...
Precision Medicine Online13d
Focus on Primary Resistance May Improve KRAS Inhibitor Strategies in Colorectal, Pancreatic Cancer
The presence of primary resistance and KRAS G12C co-mutations may explain limited single-agent efficacy of marketed KRAS inhibitors, a recent study suggests.
Business Insider11d
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
the potential of BDTX-1535 to address the unmet medical need for newly diagnosed NSCLC patients with non-classical EGFR mutations and benefit patients with NSCLC across multiple lines of therapy, the ...